171 related articles for article (PubMed ID: 36160880)
1. Neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S‑1)/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma.
Wang Z; He T; Yu D; Qin X; Geng A; Yang H
Exp Ther Med; 2022 Oct; 24(4):625. PubMed ID: 36160880
[TBL] [Abstract][Full Text] [Related]
2. Apatinib plus chemotherapy versus chemotherapy alone as neoadjuvant therapy in locally advanced gastric carcinoma patients: a prospective, cohort study.
Sun Y; Fan Y; Ye Z; Dong J; Zhang L; Peng Y
Ir J Med Sci; 2023 Jun; 192(3):1033-1040. PubMed ID: 35819743
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant PD-1 inhibitor and apatinib combined with S-1 plus oxaliplatin for locally advanced gastric cancer patients: a multicentered, prospective, cohort study.
Xu C; Xie X; Kang N; Jiang H
J Cancer Res Clin Oncol; 2023 Jul; 149(7):4091-4099. PubMed ID: 36042044
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Wan Y; Hui H; Wang X; Wu J; Sun S
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.
Chen H; Xue L; Liu L; Li P
J BUON; 2021; 26(3):917-923. PubMed ID: 34268954
[TBL] [Abstract][Full Text] [Related]
6. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
7. Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma.
Zheng Y; Wang Z; Yan C; Yan M; Hou Z; Zheng R; Zhu Z; Li C
Ann Transl Med; 2020 Dec; 8(24):1684. PubMed ID: 33490196
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant PD-1 Inhibitor Plus Apatinib and Chemotherapy Versus Apatinib Plus Chemotherapy in Treating Patients With Locally Advanced Gastric Cancer: A Prospective, Cohort Study.
Wang C; Wang Z; Zhao Y; Wang F
J Gastric Cancer; 2023 Apr; 23(2):328-339. PubMed ID: 37129156
[TBL] [Abstract][Full Text] [Related]
9. Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial.
Pan L; Tian Y; Wang K; Tang J; Liu J; Zhang J; Wang M; Liu J; Xu H; Chen X
J Gastrointest Oncol; 2022 Dec; 13(6):3300-3313. PubMed ID: 36636043
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant PD-1 inhibitor plus apatinib and chemotherapy versus apatinib plus chemotherapy versus chemotherapy alone in patients with locally advanced gastric cancer.
Xiong H; Li Y
Am J Cancer Res; 2023; 13(8):3559-3570. PubMed ID: 37693166
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer: A Nonrandomized Controlled Trial.
Lin JX; Xu YC; Lin W; Xue FQ; Ye JX; Zang WD; Cai LS; You J; Xu JH; Cai JC; Tang YH; Xie JW; Li P; Zheng CH; Huang CM
JAMA Netw Open; 2021 Jul; 4(7):e2116240. PubMed ID: 34241629
[TBL] [Abstract][Full Text] [Related]
12. The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study.
Zhang C; Wu B; Yang H; Yao Z; Zhang N; Tan F; Liu M; Xu K; Chen L; Xing J; Cui M; Su X
BMC Cancer; 2022 Nov; 22(1):1223. PubMed ID: 36443694
[TBL] [Abstract][Full Text] [Related]
13. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
14. A clinical exploration of neoadjuvant chemotherapy with tegafur, gimeracil, and oteracil potassium capsules combined with oxaliplatin for advanced gastric cancer.
Lv X; Zhang L; Huang R; Song W
Int J Clin Exp Med; 2015; 8(10):19030-6. PubMed ID: 26770529
[TBL] [Abstract][Full Text] [Related]
15. Perioperative Safety and Effectiveness of Neoadjuvant Therapy with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Plus Apatinib in Locally Advanced Gastric Cancer.
Zhang Y; Zhang B; Yang J; Zhang J; Zhang W
Cancer Manag Res; 2021; 13():2279-2286. PubMed ID: 33732020
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
[TBL] [Abstract][Full Text] [Related]
17. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L
BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort.
Jiang Q; Liu W; Zeng X; Zhang C; Du Y; Zeng L; Yin Y; Fan J; Yang M; Tao K; Zhang P
Front Immunol; 2023; 14():1122121. PubMed ID: 37215127
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301).
Miwa K; Oki E; Enomoto M; Ihara K; Ando K; Fujita F; Tominaga M; Mori S; Nakayama G; Shimokawa M; Saeki H; Baba H; Mori M; Akagi Y
BMC Cancer; 2021 Jan; 21(1):23. PubMed ID: 33402130
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects and safety of apatinib mesylate on patients with gastric carcinoma peritoneal metastasis in SOX scheme.
Wang HF; Wang HH; Ye XJ; Wang WJ; Teng LS
Eur Rev Med Pharmacol Sci; 2023 Jul; 27(14):6627-6638. PubMed ID: 37522674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]